A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine

Cardiovasc Revasc Med. 2023 Aug:53S:S313-S316. doi: 10.1016/j.carrev.2022.06.012. Epub 2022 Jun 15.

Abstract

Although coronavirus disease 2019 (COVID-19) vaccination is known to carry a slight risk of myocarditis and pericarditis, it remains unclear whether it has any impact on coronary artery disease. Here we present a case without particular thrombotic diathesis with a diagnosis of ST segment elevation acute myocardial infarction (STEMI) 19 h after a third dose of a COVID-19 mRNA vaccine. A primary percutaneous coronary intervention procedure for occluded right coronary artery with thrombus aspiration alone was successful in this patient. However, the relationship between STEMI and COVID-19 mRNA vaccination is uncertain, and additional studies to validate thrombogenetic effects of COVID-19 mRNA vaccines are needed. This case was helpful in distinguishing STEMI from myocarditis and pericarditis, which are recognized rare cardiac side effects of COVID-19 vaccination. It is important not to hesitate to perform coronary angiography procedures to rule out the possibility of STEMI occurrence, as in this case.

Keywords: Acute myocardial infarction; COVID-19; Vaccine.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / complications
  • Coronary Angiography
  • Humans
  • Myocarditis*
  • Percutaneous Coronary Intervention* / methods
  • Pericarditis*
  • ST Elevation Myocardial Infarction* / diagnostic imaging
  • ST Elevation Myocardial Infarction* / therapy
  • Thrombosis*
  • Treatment Outcome
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • mRNA Vaccines